Assessing Response Beyond Radiographic Tumor Size in Desmoid Tumor

This segment explores how clinicians evaluate treatment response in desmoid tumor, particularly when radiographic changes do not align with clinical improvement. Traditional oncology metrics often rely heavily on tumor shrinkage. However, in desmoid tumor, stable imaging may still represent meaningful therapeutic benefit. The panel explains that improvements in pain, mobility, and functional capacity are often more clinically relevant than size reduction alone. Patients may report substantial symptom relief even when imaging demonstrates minimal change. Conversely, radiographic progression without worsening symptoms may not immediately require therapy modification.

Integrating patient reported outcomes with imaging findings provides a more comprehensive assessment of benefit. This approach aligns with the evolving understanding of desmoid tumor as a chronic, locally aggressive condition in which quality of life preservation is paramount. By broadening response assessment beyond tumor measurements, clinicians can better tailor management decisions to individual patient experience and avoid unnecessary treatment changes.